BSAVA Small Animal Formulary 7E
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sebastien Lefebvre
A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sebastien Lefebvre To cite this version: Tessa Trouchon, Sebastien Lefebvre. A Review of Enrofloxacin for Veterinary Use. Open Journal of Veterinary Medicine, 2016, 6 (2), pp.40-58. 10.4236/ojvm.2016.62006. hal-01503397 HAL Id: hal-01503397 https://hal.archives-ouvertes.fr/hal-01503397 Submitted on 7 Apr 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - NoDerivatives| 4.0 International License Open Journal of Veterinary Medicine, 2016, 6, 40-58 Published Online February 2016 in SciRes. http://www.scirp.org/journal/ojvm http://dx.doi.org/10.4236/ojvm.2016.62006 A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sébastien Lefebvre USC 1233 INRA-Vetagro Sup, Veterinary School of Lyon, Marcy l’Etoile, France Received 12 January 2016; accepted 21 February 2016; published 26 February 2016 Copyright © 2016 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract This review outlines the current knowledge on the use of enrofloxacin in veterinary medicine from biochemical mechanisms to the use in the field conditions and even resistance and ecotoxic- ity. -
An Investigation of Class 1 Integrons and Integrase Gene In
AN INVESTIGATION OF CLASS 1 INTEGRONS AND INTEGRASE GENE IN ESCHERICHIA COLI AND MANNHEIMIA HAEMOLYTICA FROM BEEF CATTLE IN WESTERN CANADA A Thesis Presented to The Faculty of Graduate Studies of The University of Guelph by MATTHEW LESLIE In partial fulfillment of requirements for the degree of Master of Science May, 2011 © Matthew Leslie, 2011 Library and Archives Bibliotheque et 1*1 Canada Archives Canada Published Heritage Direction du Branch Patrimoine de I'edition 395 Wellington Street 395, rue Wellington OttawaONK1A0N4 Ottawa ON K1A 0N4 Canada Canada Your file Vote reference ISBN: 978-0-494-82791-8 Our We Notre r6f6rence ISBN: 978-0-494-82791-8 NOTICE: AVIS: The author has granted a non L'auteur a accorde une licence non exclusive exclusive license allowing Library and permettant a la Bibliotheque et Archives Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par I'lnternet, preter, telecommunication or on the Internet, distribuer et vendre des theses partout dans le loan, distribute and sell theses monde, a des fins commerciaies ou autres, sur worldwide, for commercial or non support microforme, papier, electronique et/ou commercial purposes, in microform, autres formats. paper, electronic and/or any other formats. The author retains copyright L'auteur conserve la propriete du droit d'auteur ownership and moral rights in this et des droits moraux qui protege cette these. Ni thesis. Neither the thesis nor la these ni des extraits substantiels de celle-ci substantial extracts from it may be ne doivent etre imprimes ou autrement printed or otherwise reproduced reproduits sans son autorisation. -
AMEG Categorisation of Antibiotics
12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................ -
Belgian Veterinary Surveillance of Antibacterial Consumption National
Belgian Veterinary Surveillance of Antibacterial Consumption National consumption report 2020 Publication : 22 June 2021 1 SUMMARY This annual BelVet-SAC report is now published for the 12th time and describes the antimicrobial use (AMU) in animals in Belgium in 2020 and the evolution since 2011. For the third year this report combines sales data (collected at the level of the wholesalers-distributors and the compound feed producers) and usage data (collected at farm level). This allows to dig deeper into AMU at species and farm level in Belgium. With a consumption of 87,6 mg antibacterial compounds/kg biomass an increase of +0.2% is seen in 2020 in comparison to 2019. The increase seen in 2020 is spread over both pharmaceuticals (+0.2%) and antibacterial premixes (+4.0%). This unfortunately marks the end of a successful reduction in antibacterial product sales that was seen over the last 6 years resulting in a cumulative reduction of -40,2% since 2011. The gap seen in the coverage of the sales data with the Sanitel-Med collected usage data increased substantially compared to 2019, meaning continuous efforts need to be taken to ensure completeness of the collected usage data. When looking at the evolution in the number of treatment days (BD100) at the species level, as calculated from the SANITEL- MED use data, use increased in poultry (+5,0%) and veal calves (+1,9%), while it decreased in pigs (-3,1%). However, the numerator data for this indicator remain to be updated for 2020, potentially influencing the reliability of the result. -
DANMAP 2016 - Use of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Bacteria from Food Animals, Food and Humans in Denmark
Downloaded from orbit.dtu.dk on: Oct 09, 2021 DANMAP 2016 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark Borck Høg, Birgitte; Korsgaard, Helle Bisgaard; Wolff Sönksen, Ute; Bager, Flemming; Bortolaia, Valeria; Ellis-Iversen, Johanne; Hendriksen, Rene S.; Borck Høg, Birgitte; Jensen, Lars Bogø; Korsgaard, Helle Bisgaard Total number of authors: 27 Publication date: 2017 Document Version Publisher's PDF, also known as Version of record Link back to DTU Orbit Citation (APA): Borck Høg, B. (Ed.), Korsgaard, H. B. (Ed.), Wolff Sönksen, U. (Ed.), Bager, F., Bortolaia, V., Ellis-Iversen, J., Hendriksen, R. S., Borck Høg, B., Jensen, L. B., Korsgaard, H. B., Pedersen, K., Dalby, T., Træholt Franck, K., Hammerum, A. M., Hasman, H., Hoffmann, S., Gaardbo Kuhn, K., Rhod Larsen, A., Larsen, J., ... Vorobieva, V. (2017). DANMAP 2016 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. Statens Serum Institut, National Veterinary Institute, Technical University of Denmark National Food Institute, Technical University of Denmark. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the public portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. -
NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Drug
Quantitative Safety & Epidemiology NVA237 / Glycopyrronium bromide Non-interventional Final Study Report NVA237A2401T Multinational, multi-database drug utilization study of inhaled NVA237 in Europe Author Document Status Final Date of final version 28 April 2016 of the study report EU PAS register ENCEPP/SDPP/4845 number Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis NIS Report Template Version 2.0 August-13-2014 Novartis Confidential Page 2 Non-interventional study report NVA237A/Seebri® Breezhaler®/CNVA237A2401T PASS information Title Multinational, multi-database drug utilization study of inhaled NVA237 in Europe –Final Study Report Version identifier of the Version 1.0 final study report Date of last version of 28 April 2016 the final study report EU PAS register number ENCEPP/SDPP/4845 Active substance Glycopyrronium bromide (R03BB06) Medicinal product Seebri®Breezhaler® / Tovanor®Breezhaler® / Enurev®Breezhaler® Product reference NVA237 Procedure number SeebriBreezhaler: EMEA/H/C/0002430 TovanorBreezhaler: EMEA/H/C/0002690 EnurevBreezhaler: EMEA/H/C0002691 Marketing authorization Novartis Europharm Ltd holder Frimley Business Park Camberley GU16 7SR United Kingdom Joint PASS No Research question and In the context of the NVA237 marketing authorization objectives application, the Committee for Medicinal Products for Human Use (CHMP) recommended conditions for marketing authorization and product information and suggested to conduct a post-authorization -
Pharmacology for Veterinary Medicine Students Part II by Staff Members Depatment of Pharmacology Faculty of Veterinary Medicine
Pharmacology for veterinary medicine students Part II By Staff members Depatment of Pharmacology Faculty of Veterinary Medicine Beni-Suef University 2019-2020 Item Page Drugs affecting etabolism……………………………………………….3 Antibiotics……………………………………………………………...17 Sulphonamides and Other antimicrobials……………………………….47 Antifungal drugs………………………………………………………...62 Antitubercular drugs……………………………………….………....…66 Antiparasitics………………………………………………..………….68 Antiprotozoals…………………………………………….……………78 Antiseptics and disinfectants……………………………….…….…….85 Antiviral agents…………………………………………….………..…90 Cancer chemotherapy………………………………………..………….97 Drug affecting endocrine system………………………………………101 Clinical pharmacology………………………………………….……. 116 Drug toxicology……………………………………………………… 125 Fish pharmacology…………………………………………………… 137 2 Fluids, electrolytes and acid-base therapy About 60 % of a normal animal's body weight is composed of water, fat, age, obese and older animals tend to have a small percentage of water of this 60 %, 33 % is within the body cells and is referred to as intracellular fluid compartment (ICF). The remaining 27 % is outside (between) the cells and is referred to as the extracellular fluid compartment (ECF). ECF may be further divided into sub-compartments (plasma 5 %, interstitial fluid 8 %, transcellular fluid 2 %, dense connective tissue and bone 12 %). Sodium is principally responsible for ECF osmolality. Osmolality in the ICF is principally determined by potassium, magnesium, phosphates and proteins. Na-K ATPase that is present in most cellular membranes (except for most canine and feline red blood cell membranes) maintains a very low intracellular Na concentration. Hence, if Na is added to the ECF it stays there and increases the osmolality and tonicity consequently, water is be drawn out of the ICF and into the ECF compartments until the osmolalities of the two fluid compartments are nearly equal. Chloride atoms usually follow Na atoms in order to maintain electroneurality. -
Effects of Chlortetracycline and Copper Supplementation on Levels of Antimicrobial Resistance in the Feces of Weaned Pigs
EFFECTS OF CHLORTETRACYCLINE AND COPPER SUPPLEMENTATION ON LEVELS OF ANTIMICROBIAL RESISTANCE IN THE FECES OF WEANED PIGS by GETAHUN EJETA AGGA DVM, Addis Ababa University, 2003 MSc, Utrecht University, 2008 AN ABSTRACT OF A DISSERTATION submitted in partial fulfillment of the requirements for the degree DOCTOR OF PHILOSOPHY Department of Diagnostic Medicine/Pathobiology College of Veterinary Medicine KANSAS STATE UNIVERSITY Manhattan, Kansas 2013 Abstract The use of antibiotics in food animals is of major concern as a purported cause of antimicrobial resistance (AMR) in human pathogens; as a result, alternatives to in-feed antibiotics such as heavy metals have been proposed. The effect of copper and CTC supplementation in weaned pigs on AMR in the gut microbiota was evaluated. Four treatment groups: control, copper, chlortetracycline (CTC), and copper plus CTC were randomly allocated to 32 pens with five pigs per pen. Fecal samples (n = 576) were collected weekly from three pigs per pen over six weeks and two Escherichia coli isolates per sample were tested phenotypically for antimicrobial and copper susceptibilities and genotypically for the presence of tetracycline (tet), copper (pcoD) and ceftiofur (blaCMY-2) resistance genes. CTC-supplementation significantly increased tetracycline resistance and susceptibility to copper when compared with the control group. Copper supplementation decreased resistance to most of the antibiotics, including cephalosporins, over all treatment periods. However, copper supplementation did not affect minimum inhibitory concentrations of copper or detection of pcoD. While tetA and blaCMY-2 genes were associated with a higher multi-drug resistance (MDR), tetB and pcoD were associated with lower MDR. Supplementations of CTC or copper alone were associated with increased tetB prevalence; however, their combination was paradoxically associated with reduced prevalence. -
Sous Forme De Sel De Calcium
Nom molécule Abamectine Absinthe (teinture de) Acamprosate (sous forme de sel de calcium) Acarbose Acébutolol (sous forme de chlorhydrate) Acéclofénac Acéfylline heptaminol Acémétacine Acépromazine Acépromazine (sous forme de maléate) Acétate de calcium Acétate de magnésium (sous forme de tétrahydrate) Acétate de potassium Acétate de sodium Acétate de sodium (sous forme de trihydrate) Acétazolamide Acétylcholine (sous forme de chlorure) Acétylcystéine Acétylméthionine Acétylméthionine (sous forme de sel de magnésium) Achillée millefeuille Aciclovir Acide acétylsalicylique Acide acétylsalicylique (sous forme de carbasalate de calcium) Acide acétylsalicylique (sous forme de lysinate) Acide acétylsalicylique (sous forme de sel de sodium) Acide adipique Acide alendronique (sous forme de sel de sodium) Acide alginique Acide alginique (sous forme de sel de calcium) Acide aminocaproïque Acide ascorbique Acide ascorbique (sous forme de sel de calcium) Acide ascorbique (sous forme de sel de sodium) Acide aspartique Acide aspartique (sous forme de sel de calcium) Acide aspartique (sous forme de sel de magnésium) Acide aspartique (sous forme de sel de magnésium et de potassium) Acide aspartique (sous forme de sel de magnésium et de potassium dihydraté) Acide aspartique (sous forme de sel de magnésium tétrahydraté) Acide aspartique (sous forme de sel de potassium) Acide aspartique (sous forme de sel de potassium hémihydraté) Acide aspartique (sous forme de zinc) Acide benzoïque Acide benzoïque (sous forme de benzyle) Acide benzoïque (sous forme de -
Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan -
| Hao Wanathi Movie Plena Matuma Wa Mt
|HAO WANATHI MOVIEUS009943500B2 PLENA MATUMA WA MT (12 ) United States Patent ( 10 ) Patent No. : US 9 ,943 , 500 B2 Page (45 ) Date of Patent: Apr . 17 , 2018 ( 54 ) METHODS OF TREATING TOPICAL A61K 9 /0046 ; A61K 9 / 06 ; A61K 47 /10 ; MICROBIAL INFECTIONS A61K 47 / 14 ; A61K 47 / 44 ; A61K 9 /0048 ; A61K 47/ 06 ; A61L 15 / 46 ; A61L ( 71 ) Applicant: LUODA PHARMA PTY LIMITED , 2300 /404 ; A61L 26 /0066 Caringbah ( AU ) See application file for complete search history . (72 ) Inventor : Stephen Page , Newtown ( AU ) ( 56 ) References Cited (73 ) Assignee : Luoda Pharma Pty Ltd , Caringbah U . S . PATENT DOCUMENTS (AU ) 3 ,873 , 693 A 3 / 1975 Meyers et al . 3 , 920 ,847 A * 11/ 1975 Chalaust .. .. A61K 9 /0014 Subject to any disclaimer, the term of this 514 / 512 ( * ) Notice : 4 ,772 , 470 A * 9 / 1988 Inoue .. .. .. .. .. A61K 9 / 006 patent is extended or adjusted under 35 424 / 435 U . S . C . 154 ( b ) by 0 days . 2005/ 0187199 Al * 8 /2005 Peyman .. .. .. A61K 8 / 36 514 / 154 ( 21) Appl. No .: 14 / 766 , 232 FOREIGN PATENT DOCUMENTS ( 22 ) PCT Filed : FebD . 10 , 2014 EP 0294538 A2 12 / 1988 WO WO - 2003/ 088965 A1 10 / 2003 ( 86 ) PCT No . : PCT/ AU2014 /000101 WO WO - 2006 /081327 A2 8 /2006 $ 371 ( c ) ( 1 ) , WO WO - 2008 /075207 A2 6 / 2008 ( 2 ) Date : Aug. 6 , 2015 OTHER PUBLICATIONS (87 ) PCT Pub . No .: W02014 / 121342 Weese et. al. , Veterinary Microbiology , 2010 , Elsevier, vol. 140 , pp . PCT Pub . Date : Aug . 14 , 2014 418 - 429 . * Brindle , Encyclopedia of Chemical Technology . Polyether antibi otics, Nov . 2013 , Wiley , Abstract and pp . -
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0